Frank Bennett's Email & Phone

Dr. Bennett is Senior Vice President of Research at Isis Pharmaceuticals. He is responsible for preclinical antisense drug discovery and antisense technology research. Dr. Bennett is one of the founding members of the Company. He has been involved in the development of antisense oligonucleotides as therapeutic agents, including research on the application of oligonucleotides for inflammatory, neurodegenerative diseases and cancer, oligonucleotide delivery and pharmacokinetics. He also runs the Company's antisense mechanism program which is focused on the development of RNase H, RNAi, micro-RNA and splicing. Dr. Bennett has published more than 130 papers in the field of antisense research and development and has more than 120 issued U.S. patents. Prior to joining Isis, Dr. Bennett was Associate Senior Investigator in the Department of Molecular Pharmacology at SmithKline and French Laboratories, GlaxoSmithKline (currently, GlaxoSmithKline). Dr. Bennett received his Ph.D. in Pharmacology from Baylor College of Medicine, Houston, Texas and his B.S. degree in Pharmacy from the University of New Mexico, Albuquerque, New Mexico. Dr. Bennett performed his postdoctoral research in the Department of Molecular Pharmacology at SmithKline and French Laboratories, where he studied the signal transduction pathway of leukotrienes. Dr. Bennett serves on the Advisory Board for the Experimental Therapeutics Centre in Singapore and the Scientific Committee for the American Society of Gene and Cell Therapy.